Abstract
Ischemic stroke (IS) is an acute cerebral vascular event with high mortality and morbidity. Though the precise pathophysiologic routes leading to this condition are not entirely clarified, growing evidence from animal and human experiments has exhibited the impact of non-coding RNAs in the pathogenesis of IS. Various lncRNAs namely MALAT1, linc-SLC22A2, linc-OBP2B-1, linc_luo_1172, linc-DHFRL1-4, SNHG15, linc-FAM98A-3, H19, MEG3, ANRIL, MIAT, and GAS5 are possibly involved in the pathogenesis of IS. Meanwhile, lots of miRNAs contribute in this process. Differential expression of lncRNAs and miRNAs in the sera of IS patients versus unaffected individuals has endowed these transcripts the aptitude to distinguish at risk patients. Despite conduction of comprehensive assays for evaluation of the influence of lncRNAs/miRNAs in the pathogenesis of IS, therapeutic impacts of these transcripts in IS have not been clarified. In the present paper, we review the impact of lncRNAs/miRNAs in the pathobiology of IS through assessment of evidence provided by human and animal studies.
Introduction
Ischemic stroke (IS) is an acute cerebrovascular event with high mortality and morbidity. This disorder is the third most frequent cause of mortality in Western regions of the world (Feigin et al., 2015). Current treatments for IS include thrombolysis, mechanical thromboectomy and neuroprotective therapies (Liaw and Liebeskind, 2020). Although the exact pathophysiologic routes leading to this condition are not entirely clarified, growing evidence from animal and human experiments has exhibited the impact of non-coding transcripts in the pathogenesis of IS (Zhu et al., 2019). These transcripts are highly variable in the terms of size, function, genomic location and conservation, yet in a broad classification they can be categorized based on their size to small versus long non-coding RNAs (lncRNAs). Small non-coding RNAs have some subclasses among them are microRNAs (miRNAs). Both lncRNAs and miRNAs have regulatory impacts on gene expression but via different routes. Being firstly discovered in 1993 in C. elegans (Lee et al., 1993), miRNAs comprise an ever-growing type of non-coding RNAs that target specific sequences in the 3′ untranslated regions of genes, then decreasing their expression via mRNA degradation or translation blocking (O’Brien et al., 2018). These transcripts are about 22 nucleotides in length. They can hypothetically target almost any gene in the human genome. However, the extent of miRNA response elements complementarity defines their route of action, i.e., AGO2-dependent cleavage of target transcript or RISC-associated translational suppression (Jo et al., 2015). Besides, a number of miRNAs might influence gene expression at transcriptional and post-transcriptional stages within the nucleus (O’Brien et al., 2018). However, this mode of action has not been fully discovered. The dynamic nature of miRNA-associated gene regulation potentiates them as tools for regulation of gene expression in a cell type/situation-specific mode since several events such as alternative splicing events, polyadenylation state and the presence of cell type-specific RNA binding proteins affect miRNA response elements (O’Brien et al., 2018). LncRNAs are another group of transcripts with fundamental roles in the regulation of gene transcription via several modes including acting as signal, decoy molecules, scaffolds, guide and enhancer transcripts. The chief mode action of lncRNAs is their role in the regulation of transcription in reaction to numerous stimuli through acting as molecular signals (Fang and Fullwood, 2016). Although they generally do not have open reading frame, many of them have similar characteristics with protein-coding genes among them are the presence of 5′ cap, poly A tail and alternative splicing events (Cheng et al., 2005; Derrien et al., 2012). Through participating in chromatin configuration alteration, interaction with chromatin structures, acting as competing endogenous RNAs (ceRNAs) or natural antisense lncRNAs, lncRNAs contribute in the pathogenesis of human disorders (Fang and Fullwood, 2016). Figure 1 depicts the role of a number of non-coding RNAs in the pathobiology of IS through different signaling pathways particularly PI3K/AKT and NF-κβ.
FIGURE 1
A schematic representation of the interaction between non-coding RNAs and various signaling cascades in ischemic stroke (IS). Differential expression of lncRNAs as well as miRNAs could have an important role in the pathogenesis of IS. Various miRNAs such as miR-19a, miR-122, miR-148a, miR-320d, and miR-4429 via targeting Akt, PI3K, Ras, and IKK could modulate expression of genes leukocytes, thus affecting the course of IS. In addition, miR-497 by regulating the expression levels of Bcl-2 and Bcl-w could induce ischemic neuronal death. Additionally, lncRNA H19 via directly targeting P53 could suppress neurogenesis following IS through p53/Notch1 axis. Furthermore, MEG3 could promote cell survival and reduce cell apoptosis via modulating the expression of Sema3A. Besides, KCNQ1OT1 through modulating the expression of FOXO3 could enhance brain injury and induce autophagy in IS.
Human Studies
Long Non-coding RNAs and Ischemic Stroke
Assessment of expression of lncRNAs has been the focus of numerous studies conducted in human subjects. For instance, a high throughput study has been performed on blood specimens of patients with IS and controls who have been matched with cases in terms of vascular risk factors. The study has revealed differential expression of approximately 300 lncRNAs between IS group and male controls, while 97 lncRNAs have been differentially expressed between IS group and female controls. Notably, some of differentially expressed lncRNAs have been shown to reside in genomic regions formerly recognized as IS risk loci namely lipoprotein, lipoprotein(a)-like 2, ABO blood group, prostaglandin 12 synthase, and α-adducins (Dykstra-Aiello et al., 2016). Another study has reported distinct lncRNAs signatures in peripheral blood mononuclear cells (PBMCs) among patients with IS, transient ischemic attack (TIA) and healthy subjects. Notably, expressions of linc-DHFRL1-4, SNHG15, and linc-FAM98A-3 have been substantially increased in IS patients versus healthy controls and TIA patients. Expression of linc-FAM98A-3 has been returned to normal level by day 7, whereas SNHG15 levels have been continued to be high during the follow-up period, demonstrating the capability of lncRNAs to observe IS dynamics (Deng et al., 2018). Another microarray-based assay has reported up-regulation of 560 and down-regulation of 690 lncRNAs in IS patients versus controls among them have been lncRNAs ENST00000568297, ENST00000568243, and NR_046084. Dysregulated lncRNAs have been predicted to partake in IS pathology by modulating central miRNAs, mRNAs, or IS-associated pathways (Guo et al., 2018). Assessment of lncRNA signature at two time points after IS has revealed differential expression of 3,009 and 2,034 lncRNAs 24 h and 7 days after IS, respectively. These results have shown the impact of IS on lncRNA signature at both the acute and subacute phases. Notably, expression of lncRNAs in the processing and presentation processes of antigens have been increased at 24 h and returned to basal amounts on day 7 following IS. Besides, expressions of inflammatory mediator regulation of TRP channels and GABAergic synapses have been decreased on day 7 following IS (Zhu et al., 2018). Levels of H19 in the circulation of patients with IS have been positively correlated with the National Institute of Health Stroke Scale Scores of the patients in in three time points following stroke attack. Mechanistically, H19 silencing could reduce expression of neurogenesis related proteins. In addition, H19 precludes the development of neurogenesis after IS via p53/Notch1 pathway (Wang et al., 2019a). Another experiment has reported association between H19 and Acute Stroke Treatment (TOAST) subclasses of atherosclerotic patients. Forced over-expression of H19 has enhanced ACP5 expression, increased cell proliferation and blocked cell apoptosis. Up-regulation of H19 has increased the plaque size in the animal model, thus H19 participates in the atherosclerotic processes and surges the risk of IS through increasing ACP5 levels (Huang et al., 2019). RMST is another up-regulated lncRNA in the plasma specimens of IS patients (Hou and Cheng, 2018). A previous study in Chinese Han population has shown over-expression of ANRIL in IS patients parallel with down-regulation of CDKN2A. The rs2383207 and rs1333049 SNPs have been associated with risk of IS in male subjects (Yang et al., 2018). Another study has reported higher levels of ANRIL in patients with the atrial fibrillation (AF) and ischemic stroke compared with AF patients without IS. Serum levels of ANRIL have been correlated with the NIHSS and the mRS scores (Zeng and Jin, 2020). Table 1 gives a summary of human studies reporting elevation of lncRNAs in IS.
TABLE 1
| lncRNAs | The specimen types | Numbers of clinical specimens | Cell models | Targets/Regulators | Signaling pathways | Function | References |
| ANRIL | Blood | 71 IS patients and 71 normal controls. | − | CDKN2A | − | ANRIL has a role in pathology of IS. | Yang et al., 2018 |
| ANRIL | Serum | 132 AF patients with IS and 254 AF without IS | − | − | − | Serum ANRIL is a marker in AF with IS. | Zeng and Jin, 2020 |
| GAS5 | Blood | 509 IS patients and 668 healthy controls | − | − | − | GAS5 overexpression is associated with increased IS risk. | Zheng et al., 2018 |
| H19 | 85 IS patients and 85 healthy controls | VSMC and HUVECs | ACP5 | − | H19 has enhanced ACP5 expression, increased cell proliferation and blocked cell apoptosis. | Huang et al., 2019 | |
| H19 | plasma | 40 patients with acute ischemic stroke and 25 controls | − | p53 | p53/Notch1 pathway | H19 represses neurogenesis following IS via p53/Notch1 axis. | Wang et al., 2019a |
| H19 | Plasma, neutrophils, and lymphocytes | 36 patients with anterior circulation ischemia, and 25 normal subjects | BV2 cells | HDAC1 | − | H19 induces neuroinflammatory responses. | Wang et al., 2017 |
| KCNQ1OT1 | Blood | 42 IS patients and 40 healthy controls | N2a | FOXO3 | miR−200a/FOXO3/ATG7 pathway | KCNQ1OT1 expression enhanced brain injury and induced autophagy in IS. | Wang et al., 2019a |
| linc-SLC22A2, linc-OBP2B-1, linc_luo_1172 | Blood | 133 IS patients and 133 controls | − | − | − | − | Dykstra-Aiello et al., 2016 |
| linc-DHFRL1-4, SNHG15 and linc-FAM98A-3 | Blood | 206 IS patients, 55 TIA patients and 179 controls | − | − | − | − | Deng et al., 2018 |
| lncRNA-ENST00000568297, lncRNA-ENST00000568243, NR_046084 | Blood | 50 IS patients and 50 controls | − | BCG5, FOXJ3, MAP3K5 | PI3K-Akt, p53 pathway, AMPK pathway | LncRNA-ENST00000568297 and lncRNA-ENST00000568243 Are possible diagnostic biomarkers for IS. | Guo et al., 2018 |
| lnc-CRKL-2, lnc-NTRK3-4 | serum | 100 AMS patients and 100 healthy controls | − | − | − | These new lncRNAs are markers for the detection of AMS. | Xu et al., 2020 |
| MALAT1 | Serum | 40 CIS patients and 40 healthy controls | HBMECs | VEGFA | miR-205-5p/VEGFA Pathway | MALAT1 preserves angiogenic properties of HBMECs under OGD/R circumstances. | Gao et al., 2020 |
| MEG3 | PBMCs | 20 IS patients and 20 controls. | mouse brain neuroma cell line, N2a | miR-424-5p, Sema3A | MAPK | MEG3 enhances cell survival and decreased cell apoptosis. | Xiang et al., 2020 |
| MIAT | Blood | 189 IS patients and 189 healthy controls | − | − | − | MIAT is a biomarker for discriminating IS patients from healthy persons. | Zhu et al., 2018 |
| RMST | plasma | 10 AIS patients and 10 controls | hippocampal cells | − | − | RMST induces ischemic brain injury and disrupts neurological function. | Hou and Cheng, 2018 |
| SCARNA10, TERC, LINC01481 | Blood | 10 IS and 5 controls | − | − | − | These LncRNAs play an important role in peripheral immune system changes after IS. | Zhu et al., 2019 |
Human studies showing elevation of lncRNAs in IS.
Contrary to two mentioned studies in the previous section, Feng et al. have demonstrated decreased levels of ANRIL in plasma specimens of patients with acute IS patients versus controls (Feng et al., 2019). ZFAS1 is another down-regulated lncRNA in IS patients. Moreover, expression of ZFAS1 in patients with large-artery atherosclerosis (LAA) stroke has been lower compared with those with non-LAA stroke and controls. In addition, ZFAS1 expression has been lower in the small vessel occlusion group compared with cardioembolism (Wang et al., 2019b). FLJ23867, H3F3AP6, TNPO1P1 are also among lncRNAs which are down-regulated in IS PBMCs compared with control PBMCs (Zhu et al., 2019). An lncRNA profiling using RNA-seq method and subsequent KEGG pathway and gene ontology (GO) enrichment assays have shown down-regulation of RPS6KA2-AS1 and lnc-CALM1-7 in exosomes retrieved from sera of patients with acute minor IS (Xu et al., 2020). Table 2 gives a summary of human studies that displayed under-expression of lncRNAs in IS.
TABLE 2
| lncRNAs | The specimen types | Numbers of clinical specimens | Function | References |
| ANRIL | Blood | 126 AIS patients and 125 controls | The reduced expression of ANRIL was related with higher risk of IS, higher disease severity and high inflammatory responses in acute IS patients. | Feng et al., 2019 |
| NR_036641, ENST0000079667, ENST00000507442 | Blood | 133 IS patients and 133 controls | − | Dykstra-Aiello et al., 2016 |
| ZFAS1 | 176 IS patients and 111 controls | ZFAS1 had an appropriate diagnostic value for large-artery atherosclerosis stroke | Wang et al., 2019b | |
| FLJ23867, H3F3AP6, TNPO1P1 | Blood | 10 ischemic stroke and 5 controls | These LncRNAs play an important role in peripheral immune system alterations after IS. | Zhu et al., 2019 |
| RPS6KA2-AS1, lnc-CALM1-7 | serum | 100 AMS patients and 100 healthy controls | These new lncRNAs are biomarkers AMS. | Xu et al., 2020 |
Summary of clinical investigations reporting under-expression of lncRNAs in IS.
ANRIL low-expression has been determined as a marker of better recurrence-free survival in of AF patients with IS. Based on the outcomes of Cox regression model, serum levels of ANRIL, NIH Stroke Scale (NIHSS) score, infarct volume, and smoking have been the risk factors for AF with IS (Zeng and Jin, 2020). Another study has reported that down-regulation of ANRIL in acute IS can differentiate these patients from healthy subjects with area under curve (AUC) of 0.759. Besides, expression levels of this lncRNA has been negatively correlated with NIHSS score and high-sensitivity C-reactive protein (hs-CRP), TNF-α and IL-6 concentrations, while being positively correlated with IL-10 concentrations (Feng et al., 2019). Down-regulation of ZFAS1 could predict risk of LAA strokes. Based on the results of receiver operating characteristic curve, ZFAS1 has 89.39% sensitivity in distinguishing LAA stroke patients from controls (Wang et al., 2019b). Another biomarker discovery study in PBMCs of IS patients has demonstrated AUC values of 0.73, 0.74, and 0.69 for ENST00000568297, ENST00000568243 and NR_046084, respectively (Deng et al., 2018). Moreover, MIAT levels in IS patients have been remarkably increased in correlation with NIHSS scores, mRS, hs-CRP and infarct size. Based on the results of ROC (receiver operating characteristic) curves, MIAT has been suggested as a possible marker for distinguishing IS patients from the healthy subjects with AUC value of 0.842. Moreover, patients with over-expression of MIAT had a comparatively poor prognosis. Multivariate analysis has shown the potential of MIAT as an independent prognostic biomarker of functional outcome and mortality of IS (Zhu et al., 2018). Table 3 gives a brief review of investigations that reported diagnostic/prognostic role of lncRNAs in IS.
TABLE 3
| Samples | Area under curve | Sensitivity | Specificity | Kaplan-Meier analysis | Univariate cox regression | Multivariate cox regression | References |
| Blood specimens from 126 AIS patients and 125 controls | 0.759 for ANRIL | 72.2% for ANRIL | 71.2% for ANRIL | − | − | − | Feng et al., 2019 |
| Blood specimens from 206 Ischemic stroke patients in the acute phase, 55 transient ischemic attack patients and 179 healthy controls | 0.711 for linc-DHFRL1-4, 0.756 for SNHG15, 0.659 for linc-FAM98A-3 | 0.687 for linc-DHFRL1-4, 0.594 for SNHG15, 0.594 for linc-FAM98A-3 | 0.719 for linc-DHFRL1-4, 0.844 for SNHG15, 0.688 for linc-FAM98A-3 | − | − | − | Deng et al., 2018 |
| Blood specimens from 50 patients with IS and 50 controls | 0.733 for ENST00000568297, 0.743 for ENST00000568243, 0.690 for NR_046084 | 64.8% for ENST00000568297, 70.5% for ENST00000568243, 61.5% for NR_046084 | 63.6% for ENST00000568297, 69.5% for ENST00000568243, 69.2% for NR_046084 | − | − | − | Guo et al., 2018 |
| 176 IS patients and 111 controls | 0.727 for ZFAS1 | 89.39 for ZFAS1 | 48.65 for ZFAS1 | − | − | ZFAS1 low expression was associated with risk of LAA strokes. | Wang et al., 2019b |
| Blood specimens from 71 IS patients and 71 normal controls. | 0.642 for ANRIL | 0.663 for ANRIL | 0.538 for ANRIL | − | − | − | Yang et al., 2018 |
| Blood specimens from 189 IS patients and 189 healthy controls | 0.842 for MIAT | 74.1% for MIAT | 80.4% for MIAT | Patients with over-expression of MIAT had a higher mortality compared with the low-MIAT patients. High MIAT was associated with poor prognosis. | Elevated MIAT Has been associated with IS. | MIAT was an independent prognostic indicator of functional consequences and mortality. | Zhu et al., 2018 |
| Serum specimens from 132 AF patients with IS and 254 AF without IS | 0.826 for ANRIL | 76.6% for ANRIL | 81.4% for ANRIL | Patients with lower lncRNA ANRIL expression had higher relapse-free survival compared with the high−expression group. | Serum ANRIL expression, NIHSS score, infarct size, and smoking were the risk factors for AF with IS. | Serum ANRIL expression and smoking were independent risk factors for AF with IS. | Zeng and Jin, 2020 |
Diagnostic/prognostic role of lncRNAs in stroke.
MicroRNAs and Stroke
Expression of miR-205-5p has been surged in the serum specimens of CIS patients and human brain microvascular endothelial cells under oxygen glucose deprivation/re-oxygenation. Besides, this condition has interfered with the tube formation of human brain microvascular endothelial cells. miR-205-5p knock-down has enhanced proliferation and angiogenic capacity of endothelial cells to resist oxygen glucose deprivation/re-oxygenation injury (Gao et al., 2020). The relationship between upper limb recovery after IS and miRNA signature has been assessed by another group. Authors have discovered lower levels of miR-371-3p, miR-524, miR-520g, miR-1255A, miR-453, and miR-583, while upper levels of miR-941, miR-449b, and miR-581 in good recover group compared with poor recovery group. These miRNAs have been shown to congregate on pathways related with axon guidance, developmental processes and carcinogenesis (Edwardson et al., 2018b). Expression of let-7e-5p has also been shown to be elevated in IS patients compared with control subjects. Over-expression of let-7e-5p has been associated with elevated probability of IS. This miRNA has been suggested to influence expression of four genes enriched in the MAPK pathway including CASP3 and NLK (Huang et al., 2016). miRNA levels might also distinguish IS patients from those with hemorrhagic stroke (HS). Leung et al. have demonstrated higher median plasma levels of miR-124-3p in acute phase of HS patients compared with similar phase of IS, while miR-16 had the opposite trend. Both miRNAs have been suggested as diagnostic markers for discrimination of HS from IS (Leung et al., 2014). A high throughput miRNA profiling in IS has reported differential expression of 115 miRNAs between IS cases and healthy controls. These transcripts have been linked with axon guidance, glioma, MAPK, mTOR and Erb-B signaling pathways. miR-32-3p, miR-106-5p, and miR-532-5p have been the first ranked ones (Li et al., 2015). Table 4 provides the summary of researches which reported elevation of miRNAs in IS.
TABLE 4
| microRNA | The specimen types | Numbers of clinical specimens | Cells | Targets/Regulators | Signaling pathways | Function | References |
| let-7e-5p | Blood | 302 IS patients and 302 healthy controls | U937 cell line | CASP3 and NLK | MAPK signaling pathway | Let-7e-5p might be a useful noninvasive marker for the diagnosis of IS. | Huang et al., 2016 |
| miR-145 | Blood | 32 IS patients and 18 healthy controls | − | KLF4/5 | − | MiR-145 might serve as a useful biomarker and therapy for IS. | Gan et al., 2012 |
| miR-363, miR-487b | Blood | 24 AIS patients and 24 control | − | MAP2K4 | toll-like receptor signaling pathway | These miRNA may regulate leukocyte gene expression. | Jickling et al., 2014 |
| miR-125b-2, miR-27a, miR-422a, miR-488 and miR-627 | Blood | 169 stroke patients, 24 healthy controls, and 94 individuals with metabolic syndrome | − | − | − | These miRNAs may serve as potential diagnostic biomarkers for IS. | Sepramaniam et al., 2014 |
| miR-9-5p, miR-9-3p, miR-107, miR-124-3p, and miR-128-3p | CSF | 21 IS patients and 21 controls | − | − | − | These miRNAs show the ischemia-related brain damage. | Sørensen et al., 2017 |
| miR-17-5p, miR-20b-5p, miR-27b-3p, miR-93-5p | Extracellular Vesicle in blood | 34 non-stroke and 139 stroke patients | − | − | stress/hypoxia and repair pathways | These miRNAs profile shows the development of cerebral SVD. | van Kralingen et al., 2019 |
| hsa-miR-4656, hsa-miR-432, hsa-miR-503, hsa-miR-376c, hsa-miR-130a-3p and hsa-miR-487b | PBMCs | 20 IS patients and 19 healthy controls | − | TGFB3, CELSR2 and ITM2C | − | These miRNAs regulate immune responses. | Bam et al., 2018 |
| let-7b | Plasma | 197 IS patients and 50 controls | − | − | − | Let-7b might serve as a useful noninvasive marker for the diagnosis of IS. | Long et al., 2013 |
| miR-124-3p and miR-16 | Plasma | 74 IS and 19 HS | − | − | − | miR-124-3p and miR-16 Expression levels may be the potential circulating biomarker to distinguish hemorrhagic stroke and IS. | Leung et al., 2014 |
| miR-222, miR-218, and miR-185 | Plasma | 106 AIS patients and 110 controls | − | − | − | These miRNAs might serve as promising and independent biomarkers for risk of AIS. | Jin and Xing, 2017 |
| hsa-miR-106b-5P, hsa-miR-4306 | Plasma | 136 AIS patients and 116 healthy controls | − | − | − | Enhanced expression of hsa-miR-106b-5P and hsa-miR-4306 in plasma may be novel biomarkers for the early detection of AIS. | Wang et al., 2014 |
| miR-16 | Plasma | 40 HACI patients and 30 healthy controls. | − | − | − | The high expression of miR-16 in plasma were related to TOAST and OCSP criteria. | Tian et al., 2016 |
| miR-143-3p, miR-125b-5p, miR-125a-5p | Plasma | 200 IS patients and 100 healthy controls | − | − | − | A combination of miR-125a-5p, miR-125b-5p, and miR-143-3p might have clinical utility as an early diagnostic biomarker. | Tiedt et al., 2017 |
| miR-125b-5p and miR-206 | Plasma | 94 AIS patients with or without endovascular treatment | − | − | − | miR-125b-5p and miR-206 levels are related with stroke severity. | van Kralingen et al., 2019 |
| miR-371-3p and miR-520g | Plasma | 27 IS patients | − | − | − | These miRNAs are markers of neural repair. | Edwardson et al., 2018a |
| miR-205-5p | Serum | 40 CIS patients and 40 healthy controls | HBMECs | MALAT1 | - | miR-205-5p inhibits proliferation of endothelial cells. | Gao et al., 2020 |
| miR-15a, miR-16, and miR-17-5p | Serum | 106 AIS patients and 120 healthy controls | − | − | − | Combination of miR-15a, miR-16, and miR-17-5p may be a potential AIS biomarker. | Wu et al., 2015 |
| miR-15a and miR-16 | Serum | 20 CLI patients, 122 T2D+ CLI patients, and 43 healthy controls | Circulating proangiogenic cells (PACs), VSMCs, and pericytes | VEGF-A and AKT3 | AKT signaling pathway | miR-15a/16 induces PAC survival and migration, and increases migratory capacity of PACs | Spinetti et al., 2013 |
| miR-145 | Serum | 146 AIS patients and 96 control | − | − | − | MiR-145 might serve as a useful biomarker and therapy for IS. | Jia et al., 2015 |
| miR-9 and miR-124 | Serum | 65 AIS patients and 66 control | − | − | − | Serum exosomal miR-9 and miR-124 are markers for AIS. | Ji et al., 2016 |
| miR-223 | Serum | 50 AIS patients and 33 control | − | − | − | Exosomal miR-223 levels are associated with acute IS. | Chen et al., 2017 |
| miR-146b | Serum | 128 AIS patients and 102 control | − | − | − | Elevated serum miR-146b expression might be a potential biomarker for AIS evaluation. | Chen et al., 2018b |
| miR32-3p, miR-106b-5p, miR-423-5p, miR-451a, miR-1246, miR-1299, miR-3149, and miR-4739 | Serum | 117 AIS patients and 82 healthy controls | − | − | − | These miRNAs may serve as potential diagnostic biomarkers for IS. | Li et al., 2015 |
| miR-23b-3p, miR-29b-3p, miR-181a-5p and miR-21-5p | Serum | 177 IS, 81 TIA patients and 42 controls. | − | − | − | Enhanced expression of miR-23b-3p, miR-29b-3p and miR-21–5p might distinguish between IS and TIA. | Wu et al., 2017 |
| PC-3p-57664, PC-5p-12969, hsa-miR-122-5p and hsa-miR-211-5p | Serum | 34 IS patients and 11 healthy controls. postmortem specimens from 10 IS brains and 10 control brains | lymphoblastoid cell line | − | − | These miRNAs are biomarkers for IS. | Vijayan et al., 2018 |
| let-7e | serum and cerebral spinal fluid | 72 IS patients and 51 healthy controls | − | − | − | let-7e Expression levels in serum may be the potential circulating biomarker for the acute stage of ischemic stroke. | Peng et al., 2015 |
Summary of human studies reporting elevation of miRNAs in IS.
Blood amounts of miR-30a and miR-126 have been substantially decreased in all assessed patients with IS until 24 weeks. Circulating let-7b has been decreased in patients with LAA compared with healthy subjects, while circulating let-7b have been higher in patients with other kinds of IS until 24 weeks. Notably, aberrant miRNAs levels have been resolved 48 weeks after IS onset in all patients. Authors have suggested that miR-30a might affect IS through modulation of RhoB and beclin-1. Moreover, miR-126 and let-7 can contribute in this process through modulation of VCAM-1 and inflammatory responses, respectively (Long et al., 2013). Another investigation has demonstrated that miRNA signature reveal not only the chronological development of IS but also the specific reasons for development of IS. Authors have suggested a 32-miRNA panel that can distinguish stroke etiologies during the acute phase. Moreover, miR-125b-2∗, miR-27a∗, miR-422a, miR-488, and miR-627 have been constantly dysregulated in acute stroke independent of age or severity or underlying metabolic background (Sepramaniam et al., 2014). Table 5 provides outcome of human studies reporting down-regulation of miRNAs in IS.
TABLE 5
| microRNA | The specimen types | Numbers of clinical specimens | Cell line | Targets/Regulators | Signaling pathways | Function | References |
| miR-145 | − | Primary astrocytes from rats | AQP4 | − | miR-145 protects astrocytes from damage. | Zheng et al., 2017 | |
| miR-122, miR-148a, let-7i, miR-19a, miR-320d, miR-4429 | Blood | 24 AIS patients and 24 control | − | GFR, RAS, PI3K, AKT, IKK | NF-κβ signaling | These miRNA may regulate leukocyte gene expression in IS. | Jickling et al., 2014 |
| miR-574-3p | Blood | 55 chronic stroke patients and 2360 controls | − | DBNDD2 and ELOVL1 | neurometabolic and chronic neuronal injury response pathways | miR-574-3p has a role in regulating chronic brain and systemic cellular response to stroke | Salinas et al., 2019 |
| miRNA-660-5p | Extracellular Vesicle in blood | 34 non-stroke and 139 stroke patients | − | − | − | This miRNA associated with pathophysiology of IS | van Kralingen et al., 2019 |
| hsa-miR-874-3p | PBMCs | 20 IS patients and 19 healthy controls | − | IL12A and IL12B | − | hsa-miR-874-3p involves in the immune system alteration during IS pathophysiology | Bam et al., 2018 |
| miR-30a and miR-126 | Plasma | 197 IS patients and 50 controls | − | − | − | miR-30a and miR-126 are markers of IS. | Long et al., 2013 |
| miR-126, miR-130a, and miR-378 | Plasma | 106 AIS patients and 110 controls | − | − | − | These miRNAs might serve as promising and independent biomarkers for risk of AIS. | Jin and Xing, 2017 |
| hsa-miR-320e, hsa-miR-320d | Plasma | 136 AIS patients and 116 healthy controls | − | − | − | Reduced expression of hsa-miR-320e and hsa-miR-320d is marker for early detection of AIS. | Wang et al., 2014 |
| let-7i-3p and miR-23a-3p | Plasma | 10 AIS patients and 10 healthy controls | − | − | − | These miRNAs associated with the peculiarities of clinical manifestations of IS | Zhanin et al., 2018 |
| miR-195 | Plasma | 96 AIS patients | C57BL/6 mice, BV2 microglial cells and HEK293T cells | CX3CL1 and CX3CR1 | CX3CL1/CX3CR1 signaling pathway | miR-195 has neuroprotective roles. | Guang et al., 2019 |
| miR-449b, miR-519b, miR-581, miR-616, miR-892b, miR-941, miR-1179, miR-1292, and miR-1296 | Plasma | 27 IS patients | − | − | − | These miRNAs show neural repair. | Edwardson et al., 2018a |
| miR23a and miR-221 | Serum | 146 AIS patients and 96 control | − | − | − | Jia et al., 2015 | |
| miR-124, miR-9 | Serum | 31 AIS patients and 11 control | − | MMP-9 | − | Serum miR-124, miR-9 inhibit neuroinflammation and brain injury. | Liu et al., 2015 |
| miR-224-3p, miR377-5p, miR-518b, miR-532-5p, and miR-1913 | Serum | 117 AIS patients and 82 healthy controls | − | − | − | These miRNAs in serum may be markers for IS. | Li et al., 2015 |
| miR-146a | Serum | 44 IS patients and 22 controls | − | − | − | miR-146a was decreased in patients with more severe conditions. | Kotb et al., 2019 |
| miR-1228-5p, miR-1268a, miR-1268b, miR-4433b-3p, miR-6090, miR-6752-5p, and miR6803-5p | Serum | 86 IS patients and 45 controls | − | − | − | These miRNAs forecast the risk of cerebrovascular disorder before the onset of IS. | Sonoda et al., 2019 |
| hsa-miR-22–3p, PC-3p-32463, hsa-miR-30d-5p and hsa-miR-23a-3p | Serum | 34 IS patients and 11 healthy controls. postmortem specimens from 10 IS brains and 10 control brains | lymphoblastoid cell line | − | − | These miRNAs could be used as biomarkers for IS. | Vijayan et al., 2018 |
Summary of human studies reporting down-regulation of miRNAs in IS.
Diagnostic and prognostic role of miRNAs have been appraised in IS. Elevated serum amounts of miR-15a, miR-16, and miR-17-5p in acute IS patients could be used as diagnostic markers. Based on the multivariate logistic regression analysis, serum miR-17-5p levels could discriminate the presence of acute IS. miR-15a, miR-16, and miR-17-5p had AUC values of 0.698, 0.82, and 0.784, respectively. Combination of three miRNAs increased the AUC value to 0.845 (Wu et al., 2015). ROC curve analysis has revealed AUC values of 0.91, 0.91, 0.92, and 0.93 for plasma miR-30a levels, at 24 h, 1, 4, and 24 weeks, respectively. These values have been 0.93, 0.92, 0.92, and 0.91 for miR-126 at these time points, respectively. Taken together, miR-30a, miR-126 and let-7b can be suitable biomarkers for IS (Long et al., 2013). Expression levels of miR-145 and miR-210 have been remarkably elevated in IS patients with robust AUC values of 0.90 and 1.0, respectively. Yet, dysregulation of miR-145 and miR-210 has not been exclusive for the acute phase as they have been also up-regulated in recovery phase (Sepramaniam et al., 2014). Table 6 provides summary of studies reporting diagnostic/prognostic role of miRNAs in IS.
TABLE 6
| Sample number | Area under curve | Sensitivity | Specificity | Kaplan-Meier analysis | Univariate cox regression | Multivariate cox regression | References |
| Plasma specimens from 197 IS patients and 50 controls | 0.91 for miR-30 0.92 for miR-126 0.93 for let-7b | 80% for miR-30, 84% for miR-126, 84% for let-7b | 94% for miR-30, 92% for miR-126, 92% for let-7b | − | − | − | Long et al., 2013 |
| serum and cerebral spinal fluid specimens from 72 IS patients and 51 healthy controls | 0.86 for let-7e | 82.8% | 73.4% | − | − | − | Peng et al., 2015 |
| Blood specimens from 302 IS patients and 302 healthy controls | 0.82 for let-7e-5p | − | − | − | − | − | Huang et al., 2016 |
| Serum specimens from 106 AIS patients and 120 healthy controls | 0.698 for miR-15a, 0.82 for miR-16, and 0.784 for miR-17-5p | − | − | − | − | Serum miR-17-5p is an independent marker for AIS. | Wu et al., 2015 |
| Plasma specimens from 74 IS and 19 HS | 0.70 for miR-124-3p, 0.59 for miR-16 | 68.4% for miR-124-3p, 94.7% for miR-16 | 71.2% for miR-124-3p, 35.1% for miR-16 | − | − | NIHSS, platelet count and the plasma levels of miR-124-3p were significant predictors of HS. | Leung et al., 2014 |
| Plasma specimens from 106 AIS patients and 110 controls | 0.767 for combined miRNAs | 87.7% for combined miRNAs | 54.5% for combined miRNAs | − | miR-126, miR-130a, miR-378, miR-222, miR-218, and miR-185 were predicting factors for risk of AIS. | miR-126 and miR-130a were protective factors for AIS. miR-222, miR-218, and miR-185 were risk factors for AIS. | Jin and Xing, 2017 |
| Serum specimens from 146 AIS patients and 96 control | 0.896 for miR-145, 0.816 for miR-23a, 0.819 for miR-221 | − | − | − | − | − | Jia et al., 2015 |
| Serum specimens from 65 AIS patients and 66 control | 0.8026 for miR-9, 0.6976 for miR-124 | − | − | − | − | − | Ji et al., 2016 |
| Serum specimens from 50 AIS patients and 33 control | 0.859 for miR-223 | 84.0% for miR-223 | 78.8% for miR-223 | − | − | Circulating exosomal miR-223 is risk factor for IS. | Chen et al., 2017 |
| Serum specimens from 128 AIS patients and 102 control | 0.863 for combination of hs-CRP and miR-146b | − | − | − | − | − | Chen et al., 2018b |
| Blood specimens from 169 stroke patients, 24 healthy controls, and 94 individuals with metabolic syndrome | 0.95 for miR-125b-2, 0.89 for miR-27a, 0.92 for miR-422a, 0.87 for miR-488, 0.84 for miR-627 | − | − | − | − | − | Sepramaniam et al., 2014 |
| Plasma specimens from 136 AIS patients and 116 healthy controls | 0.962 for hsa-miR-106b-5P; 0.952 for hsa-miR-4306; 0.981 for hsa-miR-320e; 0.987 for hsa-miR-320d | − | − | − | − | − | Wang et al., 2014 |
| Plasma specimens from 40 HACI patients and 30 healthy controls. | 0.775 for miR-16 | 69.7% for miR-16 | 87% for miR-16 | − | − | Patients with higher expression of MiR-16 were associated with poor prognosis. | Tian et al., 2016 |
| Plasma specimens from 200 IS patients and 100 healthy controls. | 0.93 for combination of miR-143-3p, miR-125b-5p, and miR-125a-5p | 85.6% for combination of miR-143-3p, miR-125b-5p, and miR-125a-5p | 76.3% for combination of miR-143-3p, miR-125b-5p, and miR-125a-5p | − | − | − | Tiedt et al., 2017 |
| Serum specimens from 177 IS, 81 TIA patients and 42 controls. | 0.883 for combination of miR-23b-3p, miR-29b-3p, miR-181a-5p and miR-21–5p | − | − | − | miR-23b-3p, miR-29b-3p and miR-21–5p levels were independently associated with IS. miR-23b-3p, miR-29b-3p and miR-181a-5p levels were associated with TIA. | Enhanced miR-23b-3p, miR-29b-3p, miR-181a-5p and miR-21–5p levels were closely associated with IS, and enhanced miR23b-3p, miR-29b-3p and miR-181a-5p levels were associated with TIA. | Wu et al., 2017 |
| Serum specimens from 86 IS patients and 45 controls | 0.95 for combination of miR-1268b, miR-4433b-3p, and miR-6803-5p | 84% for combination of miR-1268b, miR-4433b-3p, and miR-6803-5p | 98% for combination of miR-1268b, miR-4433b-3p, and miR-6803-5p | − | − | − | Sonoda et al., 2019 |
| Plasma specimens from 94 AIS patients with or without endovascular treatment | 0.735 for miR125b-5p | 86.36% for miR125b-5p | 55.36% for miR125b-5p | − | − | Higher expression of miR125b-5p associated with an unfavorable outcome. | van Kralingen et al., 2019 |
Diagnostic/prognostic role of miRNAs in IS.
Animal Studies
Investigations in animal models of IS have provided valuable data about the mechanisms of involvement of lncRNAs/miRNAs in IS and possible application of targeted therapies against these transcripts. For instance, expression of RMST has been elevated in primary hippocampal neurons exposed with oxygen-glucose deprivation and in animal models of IS induced by middle cerebral artery occlusion (MCAO). RMST silencing has amended brain injury in the mentioned animal model and attenuated hippocampal neuron defects (Hou and Cheng, 2018). H19 is another up-regulated lncRNA in animal models of IS whose silencing has diminished the size of brain tissue damage following middle cerebral artery obstruction and reperfusion and ameliorated the neurological defects. Mechanistically, H19 silencing could reduce expression of neurogenesis related proteins. Taken together, H19 precludes the development of neurogenesis after IS via p53/Notch1 pathway (Wang et al., 2019a). A throughput miRNA sequencing in infarcted brain regions after regional cerebral ischemia has shown up-regulation of 20 miRNAs while down-regulation of 17 miRNAs in the infarct area among them have been miR-211-5p, miR-183-5p, miR-182, and miR-96-5p which have been functionally related with some important pathways in the neurons (Duan et al., 2019). Table 7 summarizes the data regarding the roles of up-regulated non-coding RNAs in the pathogenesis of IS as revealed by animal studies.
TABLE 7
| lncRNAs/miRNAs | Animal models | Cells | Targets/Regulators | Signaling | Function | References |
| RMST | MCAO mouse model | hippocampal cells | − | − | RMST induces ischemic brain injury and disrupts neurological function. | Hou and Cheng, 2018 |
| GAS5 | brain tissues of C57BL/6 J mice | − | miR-137 | Notch1 signaling pathway | GAS5 is a ceRNA for miR-137 to control Notch1. | Chen et al., 2018a |
| Nespas | brain tissues of C57BL/6 J mice | Mouse BV2 microglial cells | TAK1 | NF-κB signaling | Nespas induces Neuroinflammation Through inhibiting NF-κB Activation | Deng et al., 2019 |
| MALAT1 | brain cortex of C57BL/6 J mice | cortical neurons of mice | Beclin1, miR-30a | − | MALAT1 induces ischemic injury and autophagy. | Guo et al., 2017 |
| H19 | C57BL/6 J mice | − | miR-675, IGF1R, pS6 kinase | IGF1 signaling pathway, mTOR pathway | H19 knockdown mice indicated amelioration on the performance of a skilled, cortical dependent motor task. | Wang et al., 2020b |
| Maclpil | C57BL/6 mice | − | LCP1 | − | Maclpil regulates the migration of macrophage and phagocytosis by LCP1. | Wang et al., 2020b |
| MEG3 | C57BL/6 J mice | N2a cell | miR-21 | miR-21/PDCD4 pathway | MEG3 promotes ischemic damage and disrupts overall neurological levels. | Zheng et al., 2017 |
| MALAT1 | C57BL/6J mice | Mouse BMECs and N2A cells | Bim and E-selectin | apoptotic pathways | Malat1 expression reduced ischemia-induced endothelial cell death in vitro | Zhang et al., 2017b |
| MEG3 | SD rats | − | BDNF, NGF and bFGF | Wnt/β-catenin signaling pathway | MEG3 reduced nerve growth and enhanced neurological damage. | You and You, 2019 |
| MEG3 | SD rats | rat brain microvascular endothelial cells | NOX4 | p53/NOX4 pathway | MEG3 was an important regulator of apoptosis. | Zhan et al., 2017 |
| ANRIL | Wistar rats | neural cells | VEGF | NF-κB signaling pathway | ANRIL increases VEGF and induces angiogenesis. | Zhang et al., 2017a |
| H19 | Wistar rats | Neural stem cell (NSC) | SUZ12, EZH2, miR-675 | oxidative response, NF-κβ signaling | H19 expression induces the proliferation and neuronal differentiation of NSCs. | Wang et al., 2020b |
| H19 | C57BL/6J mice | − | p53 | p53/Notch1 pathway | H19 represses neurogenesis after IS. | Wang et al., 2019a |
| MALAT1 | C57BL/6 J mice | Primary astrocytes | AQP4, miR-145 | − | MALAT1 induced cerebral ischemia-reperfusion damage. | Wang et al., 2020a |
| H19, Lnc-EF094477 and LncBC090003 | Wistar rats | Neural progenitor cells (NPCs) | − | − | H19 regulated post-stroke neurogenesis. | Liu et al., 2019 |
| GAS5 | C57BL/6 mice | 293 T | MAP4K4 | − | GAS5 induses neuron cell apoptosis and nerve injury in ischemic stroke through inhibiting DNMT3B-dependent MAP4K4 methylation | Deng et al., 2020b |
| MEG3 | MCAO rats | OGD/R-treated neurocytes | miR-485 and AIM2 | MEG3/miR-485/AIM2 axis | MEG3 induces cerebral ischemia reperfusion injury through elevating pyroptosis by targeting miR-485/AIM2 axis | Liang et al., 2020 |
| miR-211-5p, miR-183-5p, miR-182 and miR-96-5p | Brain of 10 Rat MCAO model and 10 controls | − | PPFIA1, SLC7A1, NTRK2, KDM48 | Ras, cGMP-PKG and phospholipase D signaling pathways | These miRNAs may control cell proliferation and apoptosis via the cGMP-PKG signaling pathway. | Duan et al., 2019 |
| miR-669c-3p | Primary cortical neuron cultures and Primary microglial cultures from C57BL/6 J neonatal mice | N2a cell line | MyD88 | toll-like receptor signaling pathway | miR-669c overexpression modulates the inflammatory responses. | Kolosowska et al., 2020 |
| miR-3473b | brain tissues from CD-1 mice | BV2 microglial cells | SOCS3 | − | The expression of miR-3473b activates microglial and the inflammation and induces neuroinflammation. | Wang et al., 2018 |
| miR-26a | Brain tissues from 48 SD rats | − | HIF-1a and VEGF | PI3K/AKT and MAPK/ERK pathway | miR-26a controls cell proliferation and angiogenesis. | Liang et al., 2018b |
| miR17-92 | C57BL/6J mice | SVZ neural progenitor cells | PTEN | Shh signaling pathway | miR17-92 induces the proliferation and viability of SVZ neural progenitor cells. | Liu et al., 2013 |
| miR-92a | mice | human endothelial cells | integrin subunit alpha5 | − | miR-92a increased angiogenesis and functional recovery of injured tissue. | Bonauer et al., 2009 |
| miR-497 | C57/B6 mice | mouse neuroblastoma (N2A) cells | bcl-2 and bcl-w | ischemia-induced cell death signaling pathway | miR-497 induces ischemic neuronal death. | Yin et al., 2010 |
| miR-130a | Brain tissue from SD rats | neurons | XIAP | − | miR−130a inhibits the proliferation, viability, and differentiation of NSCs. | Deng et al., 2020a |
| miR-125b | plasma and brain tissue specimens from 50 SD rats | PC-12 cell line | CK2α | CK2α/NADPH Oxidase Signaling pathway | miRNA-125b increases cerebral ischemia injury. | Liang et al., 2018b |
| miR-223-5p | primary cortical neurons from Wistar rat, SD rats | cortical neurons | NCKX2 | − | miR-223-5p amended ischemic damage and enhanced neurological function. | Cuomo et al., 2019 |
| miR-155 | C57BL/6 mice | endothelial cells | Dhx40, Dync1i1, Zfp652, Agtr1a | proangiogenic signaling pathway | miR-155 reduces blood flow and cerebral microvasculature. | Caballero-Garrido et al., 2015 |
| miR-155 | C57BL/6 mice | − | − | − | Mir-155 promotes ischemia/reperfusion induced brain injury and hemorrhagic transformation | Suofu et al., 2020 |
Summary of animal studies which displayed elevation of lncRNAs and miRNAs in stroke.
Meg3 is a down-regulated lncRNA after IS. Up-regulation of Meg3 has inhibited functional recovery and diminished capillary mass after IS. On the other hand, its silencing has amended brain lesions and enhanced angiogenesis after IS. Meg3 exerts these functions through inhibiting notch pathway (Liu et al., 2017). Expression of lncRNA-1810034E14Rik has also been down-regulated in LPS-exposed or oxygen-glucose deprivation-induced microglial cells. Up-regulation of 1810034E14Rik has reduced the infarct volume, ameliorated brain injury in MCAO model and decreased production of inflammatory cytokines both in the animal model and in microglial cells. Besides, 1810034E14Rik up-regulation could block the induction of microglial cells and suppress p65 phosphorylation of p65 (Qu et al., 2019). The above-mentioned examples indicate that down-regulation of lncRNAs in IS might be a compensative mechanism for amelioration of neuron damage or can be directly participate in the pathogenic mechanisms during IS. Table 8 summarizes the data regarding the roles of down-regulated non-coding RNAs in the pathogenesis of IS as revealed by animal studies.
TABLE 8
| lncRNAs/miRNAs | Animal models | Cells | Targets/Regulators | Signaling pathways | Function | References |
| Meg3 | 268 adult male Sprague–Dawley rats | HMEC-1 | NICD, Hes-1, and Hey-1 | Notch Pathway | Meg3 inhibits brain lesions, promotes neurological outcomes and induces angiogenesis after IS | Liu et al., 2017 |
| LncRNA-1810034E14Rik | C57BL/6 mice | primary microglial cells | − | NF-κB pathway | 1810034E14Rik upregulation decreased the expression of inflammatory cytokines in IS animal and inhibited the microglial cells | Qu et al., 2019 |
| HOTTIP | C57BL/6 mice | Primary cortical neurons | miR-143 | miR-143/hexokinase 2 pathway | HOTTIP expression reduced ischemic injury and attenuated glycolytic metabolism in neurons | Liang et al., 2018a |
| Lnc-M64384, Lnc-MRAK013682, Lnc-MRAK051099 | Wistar rats | Neural progenitor cells (NPCs) | − | − | Theses lncRNA may use as an therapy for amelioration of neurological functions. | Liu et al., 2019 |
| lncRNA Rian | C57BL/6 mice | N2a cell line (mouse) | miR-144-3p | Rian/miR-144-3p/GATA3 signaling | Rian inhibits cell apoptosis from cerebral ischemia-reperfusion injury by Rian/miR-144-3p/GATA3 signaling | Yao et al., 2020 |
| miR-10b-3p and miR-217-5p | Brain of 10 Rat MCAO model and 10 controls | − | PPFIA1, SLC7A1, NTRK2, KDM48 | Ras signaling pathway, cGMP-PKG signaling pathway, phospholipase D signaling pathway | These miRNAs may control cell proliferation and apoptosis via the cGMP-PKG signaling pathway | Duan et al., 2019 |
| miR-424 | plasma and ipsilateral brain tissue from C57/BL6 mice | BV2 microglial cell | CDC25A, cyclin D1, and CDK6 | − | miR-424 suppresses neuronal apoptosis and microglia activation | Zhao et al., 2013 |
| miR-126-3p and miR-126-5p | ICR mice | − | SPRED1, VEGFA, and p-Raf-1 | MAP kinase pathway, VEGFA/SPRED1/raf-1 signaling pathway | miR-126-3p reduces the OGD/R-induced apoptosis and enhances cell survival. | Xiao et al., 2020 |
| miRNA-126 | 60 ICR mice | HUVECs | PTPN9 | AKT and ERK signaling pathways | miRNA-126 reduces brain atrophy size and enhances neurobehavioral function. | Qu et al., 2019 |
| miR-22 | 16 SD rats | rat pheochromo- cytoma cell line | TNF-α, IL-1β, IL-6, IL-18, MIP-2 and PGE2 | p38 MAPK pathway | miRNA-22 inhibits the inflammatory factors in vitro. | Dong et al., 2019 |
| miR-652 | SD rats | SH-SY5Y cell lin | NOX2 | ROS pathway | miR-652 inhibited NOX2 expression, reduced NOX activity and ROS level and enhanced apoptosis | Zuo et al., 2020 |
| miR-3552 | blood and brain specimens from 7 brain specimens from MCAO rats and 5 brain specimens from sham-operated rats | − | CASP3 | apoptosis pathway | miR-3552 might regulate apoptosis by CASP3 | Li et al., 2020 |
| miR-103 | SD rats | HUVECs | VEGF | − | miR-103 inhibits the increase of tube length and the migration of cells and ischemic stroke angiogenesis, and enhances infarction volume | Shi et al., 2018 |
| miR-195 | SD rats | cerebral cortex cells RCCNC | KLF5 | JNK signaling pathway | miR-195 upregulation suppresses cerebral infarction, loss of neuronal cells, and induces synaptic plasticity | Chang et al., 2020 |
| miR-122 | Blood specimens from SD rats | − | Vcam1, Nos2, Pla2g2a | granulocyte/agranulocyte adhesion and diapedesis, leukocyte extravasation, eicosanoid signaling and atherosclerosis signaling | miR-122 upregulation enhances stroke outcomes. | Liu da et al., 2016 |
| miR-579-3p | brain tissue from SD rats | neurons | NRIP1 | NF-êB pathway | miR-579-3p has neuroprotective effect and reduces inflammation and apoptosis. | Jia et al., 2020 |
| miR-7a-5p | spontaneously hypertensive rats, C57BL/6 mice | PC12 cells | α-Syn | − | miR-7a-5p improved ischemic brain damage. | Kim et al., 2018 |
| miR-219 | Serum and brain tissue from Wistar rats | − | NMDA | − | miR-219 modulated ischemia by NMDA. | Silva et al., 2017 |
| miR-99a | C57BL/6 mice | neuro-2a cells | cyclin D1 and CDK6 | − | miR-99a decreased neuronal injury after cerebral I/R. | Tao et al., 2015 |
| miR-126 | SD rats | adipose derived stem cells (ADSCs) | − | − | miR-126 induced neurogenesis and vasculogenesis, and suppresses microglial activation and inflammatory response after ischemic stroke. | Geng et al., 2019 |
| miR-130a-3p | MCAO/R mice | SH-SY5Y and N2a cells | DAPK1 | H19/miR-130a-3p/DAPK1 axis | miR-130a-3p controls apoptosis in SH-SY5Y and N2a cells as well as on cerebral damage by I/R. | Feng et al., 2021 |
Summary of animal studies which displayed down-regulation of lncRNAs and miRNAs in stroke.
Discussion
A wealth of information about the role of non-coding RNAs in the development of IS has been obtained from combination of RNA-sequencing assays and bioinformatics assays such as GO, KEGG pathway enrichment assays and network analyses. These kinds of studies not only exhibited dysregulation of these transcripts, but also provided mechanistical insights about their route of actions. Generally, non-coding RNAs might participate in the pathophysiology of IS through different routes. As a number of differentially expressed lncRNAs between IS patients and healthy controls map to genomic loci near IS-associated genes, regulation of gene expression through cis-acting modes is a possible route. Another possible mechanism of contribution of lncRNAs in the pathology of IS is their ceRNA role. MEG3/miR-424-5p, KCNQ1OT1/miR-200a and MALAT1/miR-205-5p are few examples of interplay between lncRNAs and miRNAs in the context of IS.
Aberrant expression of non-coding RNAs in IS patients might be due to the presence of a number of genomic variants within the coding genes as demonstrated for ANRIL lncRNA. This lncRNA is among the mostly assessed lncRNAs in IS. However, the results of all studies are not consistent in this regard. Such inconsistency might be due to phase of sampling during the course of IS or the presence of other confounding parameters. The presence of lncRNAs in the serum specimens and exosomes extracted from these specimens facilitates diagnosis of IS and its clinical variants using this noninvasive route of sampling.
MicroRNAs contribute in the pathogenesis of IS through modulation of genes implicated in the atherosclerosis or inflammatory responses. Exosomal miRNAs might affect communication between several types of cells including endothelial and smooth muscle cells. IS-related circulating miRNAs might hypothetically exert similar functions. Yet, this hypothesis should be judged in upcoming studies. Peripheral expression of miRNAs can be used to differentiate IS patients from healthy subjects or IS patients from other related conditions such as HS. Moreover, their signature might predict recovery from IS-related clinical signs.
The observed sex-biased pattern of differentially expression of lncRNAs (Dykstra-Aiello et al., 2016) might determine different pathogenic processes for the evolution of IS among men and women which should be further examined. Moreover, a number of investigations have displayed specific lncRNA signatures at certain time points following IS, demonstrating the specific roles of lncRNAs in each step of pathogenic processes following IS.
In spite of conduction of various functional studies to unravel the role of non-coding RNAs in IS, therapeutic application of these transcripts have not been clarified. Therefore, future investigation should appraise the possibility of using these transcripts as therapeutic targets in IS. Another limitation of most of mentioned studies is their relatively small sample sizes and lack of simultaneous appraisal of exposures and outcomes in cross-sectional studies. Application of non-coding RNAs as therapeutic targets for IS has faced some challenges in terms of safe delivery of the drug to specific targets, avoidance of off-target effects and determination of best time for intervention. This filed is still in its infancy.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Statements
Author contributions
SG-F wrote the manuscript and revised it. MT designed the study and supervised it. NA, ZS-F, and BH collected the data and designed the figures and the tables. All authors approved the manuscript.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer RE declared a shared affiliation with several of the authors, SG-F, ZS-F, and NA, to the handling editor at the time of the review.
Abbreviations
- AF
atrial fibrillation
- AUC
area under curve
- ceRNAs
competing endogenous RNAs
- GO
gene ontology
- HS
hemorrhagic stroke
- hs-CRP
high-sensitivity C-reactive protein
- IS
Ischemic stroke
- LAA
large-artery atherosclerosis
- lncRNAs
long non-coding RNAs
- MCAO
middle cerebral artery occlusion
- miRNAs
microRNAs
- NIHSS
NIH Stroke Scale
- PBMCs
peripheral blood mononuclear cells
- ROC
receiver operating characteristic
- TIA
transient ischemic attack.
References
1
BamM.YangX.SenS.ZumbrunE. E.DennisL.ZhangJ.et al (2018). Characterization of dysregulated miRNA in Peripheral blood mononuclear cells from ischemic stroke patients.Mol. Neurobiol.551419–1429. 10.1007/s12035-016-0347-8
2
BonauerA.CarmonaG.IwasakiM.MioneM.KoyanagiM.FischerA.et al (2009). MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice.Science3241710–1713. 10.1126/science.1174381
3
Caballero-GarridoE.Pena-PhilippidesJ. C.LordkipanidzeT.BraginD.YangY.ErhardtE. B.et al (2015). In vivo inhibition of miR-155 promotes recovery after experimental mouse stroke.J. Neurosci.3512446–12464. 10.1523/jneurosci.1641-15.2015
4
ChangL.ZhangW.ShiS.PengY.WangD.ZhangL.et al (2020). microRNA-195 attenuates neuronal apoptosis in rats with ischemic stroke through inhibiting KLF5-mediated activation of the JNK signaling pathway.Mol. Med.26:31. 10.1186/s10020-020-00150-w
5
ChenF.ZhangL.WangE.ZhangC.LiX. (2018a). LncRNA GAS5 regulates ischemic stroke as a competing endogenous RNA for miR-137 to regulate the Notch1 signaling pathway.Biochem. Biophys. Res. Commun.496184–190. 10.1016/j.bbrc.2018.01.022
6
ChenY.SongY.HuangJ.QuM.ZhangY.GengJ.et al (2017). Increased circulating exosomal miRNA-223 is associated with acute ischemic stroke.Front. Neurol.8:57. 10.3389/fneur.2017.00057
7
ChenZ.WangK.HuangJ.ZhengG.LvY.LuoN.et al (2018b). Upregulated serum MiR-146b serves as a biomarker for acute ischemic stroke.Cell. Physiol. Biochem.45397–405. 10.1159/000486916
8
ChengJ.KapranovP.DrenkowJ.DikeS.BrubakerS.PatelS.et al (2005). Transcriptional maps of 10 human chromosomes at 5-nucleotide resolution.Science3081149–1154. 10.1126/science.1108625
9
CuomoO.CepparuloP.AnzilottiS.SeraniA.SirabellaR.BrancaccioP.et al (2019). Anti-miR-223-5p ameliorates ischemic damage and improves neurological function by preventing NCKX2 downregulation after ischemia in rats.Mol. Therapy Nucleic Acids181063–1071. 10.1016/j.omtn.2019.10.022
10
DengQ.-W.LiS.WangH.SunH.-L.ZuoL.GuZ.-T.et al (2018). Differential long noncoding RNA expressions in peripheral blood mononuclear cells for detection of acute ischemic stroke.Clin. Sci.1321597–1614. 10.1042/cs20180411
11
DengW.FanC.ZhaoY.MaoY.LiJ.ZhangY.et al (2020a). MicroRNA-130a regulates neurological deficit and angiogenesis in rats with ischaemic stroke by targeting XIAP.J. Cell Mol. Med.2410987–11000. 10.1111/jcmm.15732
12
DengY.ChenD.GaoF.LvH.ZhangG.SunX.et al (2020b). Silencing of long non-coding RNA GAS5 suppresses neuron cell apoptosis and nerve injury in ischemic stroke through inhibiting DNMT3B-Dependent MAP4K4 methylation.Trans. Stroke Res.11950–966. 10.1007/s12975-019-00770-3
13
DengY.ChenD.WangL.GaoF.JinB.LvH.et al (2019). Silencing of long noncoding RNA nespas aggravates microglial cell death and neuroinflammation in ischemic stroke.Stroke501850–1858. 10.1161/STROKEAHA.118.023376
14
DerrienT.JohnsonR.BussottiG.TanzerA.DjebaliS.TilgnerH.et al (2012). The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression.Genome Res.221775–1789. 10.1101/gr.132159.111
15
DongH.CuiB.HaoX. (2019). MicroRNA-22 alleviates inflammation in ischemic stroke via p38 MAPK pathways.Mol. Med. Rep.20735–744. 10.3892/mmr.2019.10269
16
DuanX.GanJ.PengD. Y.BaoQ.XiaoL.WeiL.et al (2019). Identification and functional analysis of microRNAs in rats following focal cerebral ischemia injury.Mol. Med. Rep.194175–4184. 10.3892/mmr.2019.10073
17
Dykstra-AielloC.JicklingG. C.AnderB. P.ShroffN.ZhanX.LiuD.et al (2016). Altered expression of long noncoding RNAs in blood after ischemic stroke and proximity to putative stroke risk loci.Stroke472896–2903. 10.1161/STROKEAHA.116.013869
18
EdwardsonM. A.ZhongX.CheemaA.DromerickA. (2018a). Plasma microRNA markers of upper limb recovery following human stroke.J. Clin. Trans. Sci.2:45. 10.1017/cts.2018.176
19
EdwardsonM. A.ZhongX.FiandacaM. S.FederoffH. J.CheemaA. K.DromerickA. W. (2018b). Plasma microRNA markers of upper limb recovery following human stroke.Sci. Rep.8:12558.
20
FangY.FullwoodM. J. (2016). Roles, functions, and mechanisms of long non-coding RNAs in cancer.Genom. Proteom. Bioinform.1442–54. 10.1016/j.gpb.2015.09.006
21
FeiginV. L.KrishnamurthiR. V.ParmarP.NorrvingB.MensahG. A.BennettD. A.et al (2015). Update on the global burden of ischemic and hemorrhagic stroke in 1990-2013: the GBD 2013 study.Neuroepidemiology45161–176. 10.1159/000441085
22
FengL.GuoJ.AiF. (2019). Circulating long noncoding RNA ANRIL downregulation correlates with increased risk, higher disease severity and elevated pro-inflammatory cytokines in patients with acute ischemic stroke.J. Clin. Lab. Anal.33:e22629. 10.1002/jcla.22629
23
FengM.ZhuX.ZhuoC. (2021). H19/miR-130a-3p/DAPK1 axis regulates the pathophysiology of neonatal hypoxic-ischemia encephalopathy.Neurosci. Res.16352–62. 10.1016/j.neures.2020.03.005
24
GanC.WangC.TanK. (2012). Circulatory microRNA-145 expression is increased in cerebral ischemia.Genet. Mol. Res.11147–152. 10.4238/2012.January.27.1
25
GaoC.ZhangC.-C.YangH.-X.HaoY.-N. (2020). MALAT1 protected the angiogenesis function of human brain microvascular endothelial cells (HBMECs) under oxygen glucose deprivation/re-oxygenation (OGD/R) challenge by interacting with miR-205-5p/VEGFA pathway.Neuroscience435135–145. 10.1016/j.neuroscience.2020.03.027
26
GengW.TangH.LuoS.LvY.LiangD.KangX.et al (2019). Exosomes from miRNA-126-modified ADSCs promotes functional recovery after stroke in rats by improving neurogenesis and suppressing microglia activation.Am. J. Transl. Res.11780–792.
27
GuangY.ZhendongL.LuW.XinC.XiaoxiongW.QiD.et al (2019). MicroRNA-195 protection against focal cerebral ischemia by targeting CX3CR1.J. Neurosurg. JNS1311445–1454. 10.3171/2018.5.JNS173061
28
GuoD.MaJ.YanL.LiT.LiZ.HanX.et al (2017). Down-Regulation of lncrna MALAT1 attenuates neuronal cell death through suppressing beclin1-dependent autophagy by regulating Mir-30a in cerebral ischemic stroke.Cell. Physiol. Biochem.43182–194. 10.1159/000480337
29
GuoX.YangJ.LiangB.ShenT.YanY.HuangS.et al (2018). Identification of novel LncRNA biomarkers and construction of LncRNA-Related networks in han chinese patients with ischemic stroke.Cell. Physiol. Biochem.502157–2175. 10.1159/000495058
30
HouX.-X.ChengH. (2018). Long non-coding RNA RMST silencing protects against middle cerebral artery occlusion (MCAO)-induced ischemic stroke.Biochem. Biophys. Res. Commun.4952602–2608. 10.1016/j.bbrc.2017.12.087
31
HuangS.LvZ.GuoY.LiL.ZhangY.ZhouL.et al (2016). Identification of blood Let-7e-5p as a biomarker for ischemic stroke.PLoS One11:e0163951. 10.1371/journal.pone.0163951
32
HuangY.WangL.MaoY.NanG. (2019). Long noncoding RNA-H19 contributes to atherosclerosis and induces ischemic stroke via the upregulation of acid phosphatase 5.Front. Neurol.10:32. 10.3389/fneur.2019.00032
33
JiQ.JiY.PengJ.ZhouX.ChenX.ZhaoH.et al (2016). Increased brain-specific MiR-9 and MiR-124 in the serum exosomes of acute ischemic stroke patients.PLoS One11:e0163645. 10.1371/journal.pone.0163645
34
JiaJ.CuiY.TanZ.MaW.JiangY. (2020). MicroRNA-579-3p exerts neuroprotective effects against ischemic stroke via anti-inflammation and anti-apoptosis.Neuropsychiatric Dis. Treatment161229–1238. 10.2147/ndt.s240698
35
JiaL.HaoF.WangW.QuY. (2015). Circulating miR-145 is associated with plasma high-sensitivity C-reactive protein in acute ischemic stroke patients.Cell Biochem. Funct.33314–319. 10.1002/cbf.3116
36
JicklingG. C.AnderB. P.ZhanX.NoblettD.StamovaB.LiuD. (2014). microRNA expression in peripheral blood cells following acute ischemic stroke and their predicted gene targets.PLoS One9:e99283. 10.1371/journal.pone.0099283
37
JinF.XingJ. (2017). Circulating pro-angiogenic and anti-angiogenic microRNA expressions in patients with acute ischemic stroke and their association with disease severity.Neurol. Sci.382015–2023. 10.1007/s10072-017-3071-x
38
JoM. H.ShinS.JungS.-R.KimE.SongJ.-J.HohngS. (2015). Human Argonaute 2 has diverse reaction pathways on target RNAs.Mol. Cell59117–124. 10.1016/j.molcel.2015.04.027
39
KimT.MehtaS. L.Morris-BlancoK. C.ChokkallaA. K.ChelluboinaB.LopezM.et al (2018). The microRNA miR-7a-5p ameliorates ischemic brain damage by repressing α-synuclein.Sci. Signal.11:eaat4285. 10.1126/scisignal.aat4285
40
KolosowskaN.GotkiewiczM.DhunganaH.GiudiceL.GiugnoR.BoxD.et al (2020). Intracerebral overexpression of miR-669c is protective in mouse ischemic stroke model by targeting MyD88 and inducing alternative microglial/macrophage activation.J. Neuroinflamm.17:194. 10.1186/s12974-020-01870-w
41
KotbH. G.IbrahimA. H.MohamedE. F.AliO. M.HassaneinN.BadawyD.et al (2019). The expression of microRNA 146a in patients with ischemic stroke: an observational study.Int. J. Gen. Med.12273–278. 10.2147/IJGM.S213535
42
LeeR. C.FeinbaumR. L.AmbrosV. (1993). The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14.Cell75843–854. 10.1016/0092-8674(93)90529-y
43
LeungL. Y.ChanC. P.LeungY. K.JiangH. L.AbrigoJ. M.Wang deF.et al (2014). Comparison of miR-124-3p and miR-16 for early diagnosis of hemorrhagic and ischemic stroke.Clin. Chim. Acta433139–144. 10.1016/j.cca.2014.03.007
44
LiL.DongL.ZhaoJ.HeW.ChuB.ZhangJ.et al (2020). Circulating miRNA-3552 as a potential biomarker for ischemic stroke in rats.BioMed. Res. Int.2020:4501393. 10.1155/2020/4501393
45
LiP.TengF.GaoF.ZhangM.WuJ.ZhangC. (2015). Identification of circulating MicroRNAs as potential biomarkers for detecting acute ischemic stroke.Cell Mol. Neurobiol.35433–447.
46
LiangJ.WangQ.LiJ.-Q.GuoT.YuD. (2020). Long non-coding RNA MEG3 promotes cerebral ischemia-reperfusion injury through increasing pyroptosis by targeting miR-485/AIM2 axis.Exp. Neurol.325:113139. 10.1016/j.expneurol.2019.113139
47
LiangY.XuJ.WangY.TangJ. Y.YangS. L.XiangH. G.et al (2018a). Inhibition of MiRNA-125b decreases cerebral ischemia/reperfusion injury by targeting CK2α/NADPH oxidase signaling.Cell. Physiol. Biochem.451818–1826. 10.1159/000487873
48
LiangZ.ChiY. J.LinG. Q.LuoS. H.JiangQ. Y.ChenY. K. (2018b). MiRNA-26a promotes angiogenesis in a rat model of cerebral infarction via PI3K/AKT and MAPK/ERK pathway.Eur. Rev. Med. Pharmacol. Sci.223485–3492. 10.26355/eurrev_201806_15175
49
LiawN.LiebeskindD. (2020). Emerging therapies in acute ischemic stroke.F1000Res9:F1000 Faculty Rev-546.
50
LiuJ.LiQ.ZhangK.-S.HuB.NiuX.ZhouS.-M.et al (2017). Downregulation of the long non-coding RNA Meg3 promotes angiogenesis after ischemic brain injury by activating notch signaling.Mol. Neurobiol.548179–8190. 10.1007/s12035-016-0270-z
51
LiuX. S.ChoppM.WangX. L.ZhangL.Hozeska-SolgotA.TangT.et al (2013). MicroRNA-17-92 cluster mediates the proliferation and survival of neural progenitor cells after stroke.J. Biol. Chem.28812478–12488. 10.1074/jbc.M112.449025
52
LiuX. S.FanB.WangX.ChoppM.ZhangZ. G. (2019). “Differential long noncoding RNA and messenger RNA expression profiling and functional network analysis in stroke-induced neurogenesis,” in Proceedings of the 2019 IEEE International Conference on Bioinformatics and Biomedicine (BIBM), (Piscataway, NJ: IEEE).
53
LiuY.ZhangJ.HanR.LiuH.SunD.LiuX. (2015). Downregulation of serum brain specific microRNA is associated with inflammation and infarct volume in acute ischemic stroke.J. Clin. Neurosci.22291–295. 10.1016/j.jocn.2014.05.042
54
Liu daZ.JicklingG. C.AnderB. P.HullH.ZhanX.CoxC.et al (2016). Elevating microRNA-122 in blood improves outcomes after temporary middle cerebral artery occlusion in rats.J. Cereb. Blood Flow Metab.361374–1383. 10.1177/0271678X15610786
55
LongG.WangF.LiH.YinZ.SandipC.LouY.et al (2013). Circulating miR-30a, miR-126 and let-7b as biomarker for ischemic stroke in humans.BMC Neurol.13:178. 10.1186/1471-2377-13-178
56
O’BrienJ.HayderH.ZayedY.PengC. (2018). Overview of microRNA biogenesis, mechanisms of actions, and circulation.Front. Endocrin.9:402. 10.3389/fendo.2018.00402
57
PengG.YuanY.WuS.HeF.HuY.LuoB. (2015). MicroRNA let-7e is a potential circulating biomarker of acute stage ischemic stroke.Trans. Stroke Res.6437–445. 10.1007/s12975-015-0422-x
58
QuM.PanJ.WangL.ZhouP.SongY.WangS.et al (2019). MicroRNA-126 regulates angiogenesis and neurogenesis in a mouse model of focal cerebral ischemia.Mol. Therapy Nucleic Acids1615–25. 10.1016/j.omtn.2019.02.002
59
SalinasJ.LinH.AparicoH. J.HuanT.LiuC.RongJ.et al (2019). Whole blood microRNA expression associated with stroke: results from the framingham heart study.PLoS One14:e0219261. 10.1371/journal.pone.0219261
60
SepramaniamS.TanJ.-R.TanK.-S.DeSilvaD. A.TavintharanS.WoonF.-P.et al (2014). Circulating microRNAs as biomarkers of acute stroke.Int. J. Mol. Sci.151418–1432.
61
ShiF.-P.WangX.-H.ZhangH.-X.ShangM.-M.LiuX.-X.SunH.-M.et al (2018). MiR-103 regulates the angiogenesis of ischemic stroke rats by targeting vascular endothelial growth factor (VEGF).Iran. J. Basic Med. Sci.21318–324. 10.22038/IJBMS.2018.27267.6657
62
SilvaC. I.NovaisP. C.RodriguesA. R.CarvalhoC. A. M.ColliB. O.CarlottiC. G.Jr.et al (2017). Expression of NMDA receptor and microRNA-219 in rats submitted to cerebral ischemia associated with alcoholism.Arquivos de Neuro-Psiquiatria7530–35. 10.1590/0004-282X20160188
63
SonodaT.MatsuzakiJ.YamamotoY.SakuraiT.AokiY.TakizawaS.et al (2019). Serum MicroRNA-Based risk prediction for stroke.Stroke501510–1518. 10.1161/STROKEAHA.118.023648
64
SørensenS. S.NygaardA.-B.CarlsenA. L.HeegaardN. H. H.BakM.ChristensenT. (2017). Elevation of brain-enriched miRNAs in cerebrospinal fluid of patients with acute ischemic stroke.Biomarker Res.5:24. 10.1186/s40364-017-0104-9
65
SpinettiG.FortunatoO.CaporaliA.ShantikumarS.MarchettiM.MeloniM.et al (2013). MicroRNA-15a and microRNA-16 impair human circulating proangiogenic cell functions and are increased in the proangiogenic cells and serum of patients with critical limb ischemia.Circ. Res.112335–346. 10.1161/CIRCRESAHA.111.300418
66
SuofuY.WangX.HeY.LiF.ZhangY.CarlisleD. L.et al (2020). Mir-155 knockout protects against ischemia/reperfusion-induced brain injury and hemorrhagic transformation.NeuroReport31235–239. 10.1097/WNR.0000000000001382
67
TaoZ.ZhaoH.WangR.LiuP.YanF.ZhangC.et al (2015). Neuroprotective effect of microRNA-99a against focal cerebral ischemia-reperfusion injury in mice.J. Neurol. Sci.355113–119. 10.1016/j.jns.2015.05.036
68
TianC.LiZ.YangZ.HuangQ.LiuJ.HongB. (2016). Plasma MicroRNA-16 is a biomarker for diagnosis, stratification, and prognosis of hyperacute cerebral infarction.PLoS One11:e0166688. 10.1371/journal.pone.0166688
69
TiedtS.PrestelM.MalikR.SchieferdeckerN.DueringM.KautzkyV.et al (2017). RNA-Seq identifies circulating miR-125a-5p, miR-125b-5p, and miR-143-3p as potential biomarkers for acute ischemic stroke.Circ. Res.121970–980. 10.1161/CIRCRESAHA.117.311572
70
van KralingenJ. C.McFallA.OrdE. N. J.CoyleT. F.BissettM.McClureJ. D.et al (2019). Altered extracellular vesicle microRNA expression in ischemic stroke and small vessel disease.Trans. Stroke Res.10495–508. 10.1007/s12975-018-0682-3
71
VijayanM.KumarS.YinX.ZaferD.ChananaV.CengizP.et al (2018). Identification of novel circulatory microRNA signatures linked to patients with ischemic stroke.Hum. Mol. Genet.272318–2329. 10.1093/hmg/ddy136
72
WangH.ZhengX.JinJ.ZhengL.GuanT.HuoY.et al (2020a). LncRNA MALAT1 silencing protects against cerebral ischemia-reperfusion injury through miR-145 to regulate AQP4.J. Biomed. Sci.27:40. 10.1186/s12929-020-00635-0
73
WangJ.CaoB.ZhaoH.GaoY.LuoY.ChenY.et al (2019a). Long noncoding RNA H19 prevents neurogenesis in ischemic stroke through p53/Notch1 pathway.Brain Res. Bull.150111–117. 10.1016/j.brainresbull.2019.05.009
74
WangJ.RuanJ.ZhuM.YangJ.DuS.XuP.et al (2019b). Predictive value of long noncoding RNA ZFAS1 in patients with ischemic stroke.Clin. Exp. Hypertens41615–621. 10.1080/10641963.2018.1529774
75
WangJ.ZhaoH.FanZ.LiG.MaQ.TaoZ.et al (2017). Long noncoding RNA H19 promotes neuroinflammation in ischemic stroke by driving histone deacetylase 1-Dependent M1 microglial polarization.Stroke482211–2221. 10.1161/STROKEAHA.117.017387
76
WangW.SunG.ZhangL.ShiL.ZengY. (2014). Circulating microRNAs as novel potential biomarkers for early diagnosis of acute stroke in humans.J. Stroke Cereb. Dis.232607–2613. 10.1016/j.jstrokecerebrovasdis.2014.06.002
77
WangX.ChenS.NiJ.ChengJ.JiaJ.ZhenX. (2018). miRNA-3473b contributes to neuroinflammation following cerebral ischemia.Cell Death Dis.9:11. 10.1038/s41419-017-0014-7
78
WangY.LuoY.YaoY.JiY.FengL.DuF.et al (2020b). Silencing the lncRNA Maclpil in pro-inflammatory macrophages attenuates acute experimental ischemic stroke via LCP1 in mice.J. Cereb. Blood Flow Metab.40747–759. 10.1177/0271678X19836118
79
WuJ.DuK.LuX. (2015). Elevated expressions of serum miR-15a, miR-16, and miR-17-5p are associated with acute ischemic stroke.Int. J. Clin. Exp. Med.821071–21079.
80
WuJ.FanC. L.MaL. J.LiuT.WangC.SongJ. X.et al (2017). Distinctive expression signatures of serum microRNAs in ischaemic stroke and transient ischaemic attack patients.Thrombosis Haemostasis117992–1001. 10.1160/TH16-08-0606
81
XiangY.ZhangY.XiaY.ZhaoH.LiuA.ChenY. (2020). LncRNA MEG3 targeting miR-424-5p via MAPK signaling pathway mediates neuronal apoptosis in ischemic stroke.Aging123156–3174. 10.18632/aging.102790
82
XiaoZ. H.WangL.GanP.HeJ.YanB. C.DingL. D. (2020). Dynamic changes in miR-126 expression in the hippocampus and penumbra following experimental transient global and focal cerebral ischemia–reperfusion.Neurochem. Res.451107–1119. 10.1007/s11064-020-02986-4
83
XuX.ZhuangC.ChenL. (2020). Exosomal long non-coding RNA expression from serum of patients with acute minor stroke.Neuropsychiatric Dis. Treatment16:153. 10.2147/NDT.S230332
84
YangJ.GuL.GuoX.HuangJ.ChenZ.HuangG.et al (2018). LncRNA ANRIL expression and ANRIL gene polymorphisms contribute to the risk of ischemic stroke in the chinese han population.Cell Mol. Neurobiol.381253–1269. 10.1007/s10571-018-0593-6
85
YaoP.LiY.-L.ChenY.ShenW.WuK.-Y.XuW.-H. (2020). Overexpression of long non-coding RNA Rian attenuates cell apoptosis from cerebral ischemia-reperfusion injury via Rian/miR-144-3p/GATA3 signaling.Gene737:144411. 10.1016/j.gene.2020.144411
86
YinK.-J.DengZ.HuangH.HamblinM.XieC.ZhangJ.et al (2010). miR-497 regulates neuronal death in mouse brain after transient focal cerebral ischemia.Neurobiol. Dis.3817–26. 10.1016/j.nbd.2009.12.021
87
YouD.YouH. (2019). Repression of long non-coding RNA MEG3 restores nerve growth and alleviates neurological impairment after cerebral ischemia-reperfusion injury in a rat model.Biomed. Pharmacotherapy1111447–1457. 10.1016/j.biopha.2018.12.067
88
ZengW.JinJ. (2020). The correlation of serum long non-coding RNA ANRIL with risk factors, functional outcome, and prognosis in atrial fibrillation patients with ischemic stroke.J. Clin. Lab. Anal.34:e23352. 10.1002/jcla.23352
89
ZhanR.XuK.PanJ.XuQ.XuS.ShenJ. (2017). Long noncoding RNA MEG3 mediated angiogenesis after cerebral infarction through regulating p53/NOX4 axis.Biochem. Biophys. Res. Commun.490700–706. 10.1016/j.bbrc.2017.06.104
90
ZhangB.WangD.JiT.-F.ShiL.YuJ.-L. (2017a). Overexpression of lncRNA ANRIL up-regulates VEGF expression and promotes angiogenesis of diabetes mellitus combined with cerebral infarction by activating NF-κB signaling pathway in a rat model.Oncotarget817347–17359. 10.18632/oncotarget.14468
91
ZhangX.TangX.LiuK.HamblinM. H.YinK.-J. (2017b). Long noncoding RNA Malat1 regulates cerebrovascular pathologies in ischemic stroke.J. Neurosci.371797–1806. 10.1523/jneurosci.3389-16.2017
92
ZhaninI. S.GusarV. A.TimofeevaA. T.PinelisV. G.AsanovA. Y. (2018). MicroRNA expression profile in patients in the early stages of ischemic stroke.Neurol. Neuropsychiatry Psychosomat.1072–78. 10.1016/j.jpsychires.2019.05.018
93
ZhaoH.WangJ.GaoL.WangR.LiuX.GaoZ.et al (2013). MiRNA-424 protects against permanent focal cerebral ischemia injury in mice involving suppressing microglia activation.Stroke441706–1713. 10.1161/STROKEAHA.111.000504
94
ZhengL.ChengW.WangX.YangZ.ZhouX.PanC. (2017). Overexpression of MicroRNA-145 ameliorates astrocyte injury by targeting aquaporin 4 in cerebral ischemic stroke.BioMed. Res. Int.2017:9530951. 10.1155/2017/9530951
95
ZhengZ.LiuS.WangC.HanX. (2018). A functional polymorphism rs145204276 in the promoter of long noncoding RNA GAS5 is associated with an increased risk of ischemic stroke.J. Stroke Cereb. Dis.273535–3541. 10.1016/j.jstrokecerebrovasdis.2018.08.016
96
ZhuM.LiN.LuoP.JingW.WenX.LiangC.et al (2018). Peripheral blood leukocyte expression of lncRNA MIAT and its diagnostic and prognostic value in ischemic stroke.J. Stroke Cereb. Dis.27326–337. 10.1016/j.jstrokecerebrovasdis.2017.09.009
97
ZhuW.TianL.YueX.LiuJ.FuY.YanY. (2019). LncRNA expression profiling of ischemic stroke during the transition from the acute to subacute stage.Front. Neurol.10:36. 10.3389/fneur.2019.00036
98
ZuoM.-L.WangA.-P.SongG.-L.YangZ.-B. (2020). miR-652 protects rats from cerebral ischemia/reperfusion oxidative stress injury by directly targeting NOX2.Biomed. Pharmacotherapy.124:109860. 10.1016/j.biopha.2020.109860
Summary
Keywords
lncRNA, miRNA, stroke, expression, biomarker
Citation
Ghafouri-Fard S, Shirvani-Farsani Z, Hussen BM, Taheri M and Arefian N (2021) Emerging Impact of Non-coding RNAs in the Pathology of Stroke. Front. Aging Neurosci. 13:780489. doi: 10.3389/fnagi.2021.780489
Received
21 September 2021
Accepted
28 October 2021
Published
19 November 2021
Volume
13 - 2021
Edited by
Li Li, Capital Medical University, China
Reviewed by
Laurent Metzinger, University of Picardie Jules Verne, France; Atefe Abak, Tabriz University of Medical Sciences, Iran; Ilgiz Fanilevich Gareev, First Affiliated Hospital of Harbin Medical University, China; Hazha Hidayat, Salahaddin University, Iraq; Reyhane Eghtedarian, Shahid Beheshti University, Iran
Updates
Copyright
© 2021 Ghafouri-Fard, Shirvani-Farsani, Hussen, Taheri and Arefian.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Mohammad Taheri, Mohammad_823@yahoo.comNoormohammad Arefian, narefian@yahoo.com
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.